Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

About this update from Tenaya Therapeutics, Inc.

Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif. , Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3 -associated hypertrophic cardiomyopathy (HCM) on Tuesday, December 17 . Conference Call and Webcast Tenaya management will host a live webcast and conference call to review the initial data from MyPEAK-1 on Tuesday, December 17 th, 2024 at 8:00 a.m. ET . To access the live webcast, participants may register here . The live webcast will be available under the "Events” section of the Investor Relations page of the Tenaya website at investors.tenayatherapeutics.com . An archived replay of the webcast will be available on Tenaya’s website. About Tenaya Therapeutics Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya’s pipeline includes TN-201, a gene therapy for MYBPC3 -associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2 -associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit www.tenayatherapeutics.com . Tenaya Contacts Michelle Corral VP, Corporate Communications and Investor Relations [email protected] Investors Anne-Marie Fields Precision AQ [email protected] Media Wendy Ryan Ten Bridge Communications [email protected] Source: Tenaya Therapeutics, Inc.

View stock analysis, news, and events for Tenaya Therapeutics, Inc.